Role of colloidal drug delivery carriers in taxane-mediated chemotherapy: A review

Current Pharmaceutical Design

Volumn 22, Issue 33, 2016, Pages 5127-5143

  Kumar, Pramod ^a   Raza, Kaisar ^a   Kaushik, Lokesh ^a   Malik, Ruchi ^a   Arora, Shweta ^b   Katare, Om Prakash ^c  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

^b BANASTHALI UNIVERSITY   (India)

^c PANJAB UNIVERSITY   (India)

Author keywords

Cabazitaxel; CNTs; Dendrimers; Docetaxel; Emulsions; Ethosomes; Liposomes; Mixed micelles; Nanoparticles; NDDS; Niosomes; Paclitaxel

Indexed keywords

CABAZITAXEL; DENDRIMER; DOCETAXEL; LIPOSOME; NANOCARRIER; NIOSOME; PACLITAXEL; SOLID LIPID NANOPARTICLE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DRUG CARRIER; TAXANE; TAXOID;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STABILITY; ENCAPSULATION; HUMAN; MICELLE; NANOEMULSION; PERMEABILITY; PRIORITY JOURNAL; REVIEW; THERAPEUTIC INDEX; BREAST TUMOR; CHEMISTRY; COLLOID; FEMALE; LUNG TUMOR; MALE; NON SMALL CELL LUNG CANCER; OVARY TUMOR; PROSTATE TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED-RING COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; COLLOIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84984809120     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160524144926     Document Type: Review

References (191)

1. The World Health Organization’s fight against cancer: strategies that prevent, cure and care. USA: WHO 2007.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer J Clin 2015; 65 (1): 5-29.
3. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5 (1): 65-72.
4. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des 2010; 16 (1): 3-10.
5. Nabholtz J-M, Gligorov J. The role of taxanes in the treatment of breast cancer. Exp Opin Pharmacother 2005; 6 (7): 1073-94.
6. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93 (9): 2325-7.
7. Fauzee NJS, Dong Z, Wang Y. Taxanes: promising anti-cancer drugs. Asian Pac J Cancer Prev 2011; 12 (4): 837-51.
8. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Develop Ther 2012; 6: 371.
9. Two thirds of the patients enrolled in the Paclical® Phase III study Sweden: Oasmia Pharmaceutical AB; 2015; [updated 07/04/2015; cited 2015 07/04/2015]. Available from: http: //www.oasmia.com/news.asp?c_id=184.
10. Abal M, Andreu J, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3 (3): 193-203.
11. Horwitz S. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1993; 5: S3-6.
12. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005; 6 (4): 229-39.
13. Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nursing 2009; 13 (1): 49-59.
14. Biganzoli L, Licitra S, Moretti E, Pestrin M, Zafarana E, Di Leo A. Taxanes in the elderly: Can we gain as much and be less toxic? Critic Rev Oncol/Hematol 2009; 70 (3): 262-71.
15. Jones S. Head-to-head: docetaxel challenges paclitaxel. Eur J Cancer Suppl 2006; 4 (4): 4-8.
16. Singh S, Dash AK. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev™ Therap Drug Carrier Syst 2009; 26 (4): 333-72.
17. Surapaneni MS, Das SK, Das NG. Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol 2012; 2012.
18. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol 2010; 76 (6): 612.
19. Hennenfent K, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006; 17 (5): 735-49.
20. Raza K, Kumar M, Kumar P, et al. Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems. BioMed Res Int 2014; 2014.
21. Fairhurst D, Lee RW. Observations on nanotechnology-based drug delivery approaches: translating nanotechnology from bench to pharmaceutical market: barriers, success, and promises. Am Pharm Rev 2012; 127536.
22. Eifler AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol 2011; 726: 325-38.
23. Chien YW, Swarbrick J. Novel drug delivery systems. 2nd ed. New York: Dekker 1992.
24. Sharma A, Straubinger RM. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 1994; 11 (6): 889-96.
25. Sharma D, Chelvi T, Kaur J, Ralhan R. Short communication: Thermosensitive liposomal taxol formulation: heatmediated targeted drug delivery in murine melanoma. Melanoma Res 1998; 8 (3): 240-4.
26. Ceruti M, Crosasso P, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J Control Release 2000; 63 (1): 141-53.
27. Wu J, Liu Q, Lee RJ. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 2006; 316 (1): 148-53.
28. Yan F, Li L, Deng Z, et al. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. J Control Release 2013; 166 (3): 246-55.
29. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 2003; 91 (3): 417-29.
30. Zhai G, Wu J, Xiang G, et al. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol 2009; 9 (3): 2155.
31. Yuan M, Zhu F, Lou J, et al. The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer. Drug Res 2014; 64 (04): 195-202.
32. Zhai G, Wu J, Yu B, Guo C, Yang X, Lee RJ. A transferrin receptor-targeted liposomal formulation for docetaxel. J Nanosci Nanotechnol 2010; 10 (8): 5129-36.
33. Muthu MS, Kulkarni SA, Raju A, Feng S-S. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 2012; 33 (12): 3494-501.
34. Yuan Z, Chen D, Zhang S, Zheng Z. Preparation, characterization and evaluation of docetaxel-loaded, folate-conjugated PEGliposomes. Yakugaku Zasshi 2010; 130 (10): 1353-9.
35. Zhao L, Wei Y, Li W, et al. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. J Drug Targeting 2011; 19 (3): 171-8.
36. Li J, Xu H, Ke X, Tian J. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid. J Drug Targeting 2012; 20 (5): 467-73.
37. Raju A, Muthu MS, Feng S-S. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Exp Opin Drug Deliv 2013; 10 (6): 747-60.
38. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 2010; 99 (4): 2049-60.
39. Zarei M, Norouzian D, Honarvar B, Mohammadi M, Shamabadi HE, Akbarzadeh A. Paclitaxel loaded niosome nanoparticle formulation prepared via reverse phase evaporation method: an in vitro evaluation. Pak J Biol Sci 2013; 16 (6): 295-8.
40. Paolino D, Celia C, Trapasso E, Cilurzo F, Fresta M. Paclitaxelloaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm 2012; 81 (1): 102-12.
41. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001; 72 (1): 191-202.
42. Liang H, Yang Q, Deng L, Lu J, Chen J. Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug Develop Indus Pharm 2011; 37 (5): 597-605.
43. Wei Z, Hao J, Yuan S, et al. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int J Pharm 2009; 376 (1): 176-85.
44. Dahmani FZ, Yang H, Zhou J, Yao J, Zhang T, Zhang Q. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci 2012; 47 (1): 179-89.
45. Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release 2005; 101 (1): 59-68.
46. Lee SC, Huh KM, Lee J, Cho YW, Galinsky RE, Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules 2007; 8 (1): 202-8.
47. Kim S, Kim JY, Huh KM, Acharya G, Park K. Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Control Release 2008; 132 (3): 222-9.
48. Zhang L, He Y, Ma G, Song C, Sun H. Paclitaxel-loaded polymeric micelles based on poly (ɛ-caprolactone)-poly (ethylene glycol)-poly (ɛ-caprolactone) triblock copolymers: in vitro and in vivo evaluation. Nanomed: Nanotechnol, Biol Med 2012; 8 (6): 925-34.
49. Li Y, Yang F, Chen W, et al. A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading ca pacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study. Chem Pharm Bull 2012; 60 (9): 1146-54.
50. Zhang C, Qu G, Sun Y, et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008; 29 (9): 1233-41.
51. Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res 2003; 20 (2): 297-302.
52. Soga O, van Nostrum CF, Fens M, et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 2005; 103 (2): 341-53.
53. Salmaso S, Bersani S, Pirazzini M, Caliceti P. pH-sensitive PEGbased micelles for tumor targeting. J Drug Target 2011; 19 (4): 303-13.
54. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release 2008; 126 (2): 122-9.
55. Liu S, Tong Y, Yang Y. Thermally sensitive micelles selfassembled from poly (N-isopropylacrylamide-co-N, Ndimethylacrylamide)-b-poly (D, L-lactide-co-glycolide) for controlled delivery of paclitaxel. Mol BioSyst 2005; 1 (2): 158-65.
56. Alani AW, Bae Y, Rao DA, Kwon GS. Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel. Biomaterials 2010; 31 (7): 1765-72.
57. Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG 2000-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: Enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci 2012; 46 (1): 64-71.
58. Alkan-Onyuksel H, Ramakrishnan S, Chai H-B, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm Res 1994; 11 (2): 206-12.
59. Han L-M, Guo J, Zhang L-J, Wang Q-S, Fang X-L. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 2006; 27 (6): 747-53.
60. Seow WY, Xue JM, Yang Y-Y. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials 2007; 28 (9): 1730-40.
61. Wang Y, Li Y, Zhang L, Fang X. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles. Arch Pharmacal Res 2008; 31 (4): 530-8.
62. Zhao Y, Li Y, Ge J, Li N, Li L-B. Pluronic-poly (acrylic acid)-cysteine/Pluronic L121 mixed micelles improve the oral bioavailability of paclitaxel. Drug Develop Ind Pharm 2014; 40 (11): 1483-93.
63. You J, Wang Z, Du Y, et al. Specific tumor delivery of paclitaxel using glycolipid-like polymer micelles containing gold nanospheres. Biomaterials 2013; 34 (18): 4510-9.
64. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly (ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005; 13 (1): 73-80.
65. Katragadda U, Teng Q, Rayaprolu BM, Chandran T, Tan C. Multidrug delivery to tumor cells via micellar nanocarriers. Int J Pharm 2011; 419 (1): 281-6.
66. Li Y, Bi Y, Xi Y, Li L. Enhancement on oral absorption of paclitaxel by multifunctional pluronic micelles. J Drug Target 2013; 21 (2): 188-99.
67. Mi Y, Liu Y, Feng S-S. Formulation of Docetaxel by folic acidconjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS 2k) micelles for targeted and synergistic chemotherapy. Biomaterials 2011; 32 (16): 4058-66.
68. Lee S-W, Yun M-H, Jeong SW, et al. Development of docetaxelloaded intravenous formulation, Nanoxel-PM™ using polymerbased delivery system. J Controlled Release 2011; 155 (2): 262-71.
69. Tong S-W, Xiang B, Dong D-W, Qi X-R. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 2012; 434 (1): 413-9.
70. Muthu MS, Avinash Kulkarni S, Liu Y, Feng S-S. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine 2012; 7 (3): 353-64.
71. Chen L, Sha X, Jiang X, Chen Y, Ren Q, Fang X. Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. Int J Nanomed 2013; 8: 73.
72. Zhao J, Mi Y, Feng S-S. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials 2013; 34 (13): 3411-21.
73. Wu L, Tang C, Yin C. Preparation and characterization of paclitaxel delivery system based on semi-solid lipid nanoparticles coated with poly (ethylene glycol). Pharmazie 2010; 65 (7): 493-9.
74. Lee M-K, Lim S-J, Kim C-K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28 (12): 2137-46.
75. Pandita D, Ahuja A, Velpandian T, Lather V, Dutta T, Khar R. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie 2009; 64 (5): 301-10.
76. Videira M, Almeida AJ, Fabra À. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomed Nanotechnol Biol Med 2012; 8 (7): 1208-15.
77. Sahu PK, Mishra DK, Jain N, Rajoriya V, Jain AK. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel. Drug Develop Ind Pharm 2014 (0): 1-10.
78. Wu L, Tang C, Yin C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly (ethylene glycol). Drug Develop Ind Pharm 2010; 36 (4): 439-48.
79. Yu YH, Kim E, Park DE, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm 2012; 80 (2): 268-73.
80. Zheng J, Wan Y, Elhissi A, Zhang Z, Sun X. Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles. Pharm Res 2014: 31 (8): 2220-33.
81. Pandey V, Gajbhiye KR, Soni V. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Drug Deliv 2015; 22 (2): 199-205.
82. Cho H-J, Park JW, Yoon I-S, Kim D-D. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomed 2014; 9: 495.
83. Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009; 30 (2): 226-32.
84. Gao Y, Yang R, Zhang Z, Chen L, Sun Z, Li Y. Solid lipid nanoparticles reduce systemic toxicity of docetaxel: Performance and mechanism in animal. Nanotoxicology 2011; 5 (4): 636-49.
85. Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: Preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci 2013; 102 (6): 1994-2004.
86. Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams III RO, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm 2014; 11 (4): 1239-49.
87. Zhu X, Huang S, Xie Y, et al. Folic acid mediated solid lipid nanocarriers loaded with docetaxel and oxidized single-walled carbon nanotubes. J Nanoparticle Res 2014; 16 (1): 1-10.
88. Li S, Su Z, Sun M, et al. An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery. Int J Pharm 2012; 436 (1): 248-57.
89. Emami J, Rezazadeh M, Varshosaz J. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater 2012; 2012: 3.
90. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Controlled Release 2013; 171 (3): 349-57.
91. Yang X-Y, Li Y-X, Li M, Zhang L, Feng L-X, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013; 334 (2): 338-45.
92. Li X, Wang D, Zhang J, Pan W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J Pharm Pharmacol 2009; 61 (11): 1485-92.
93. Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 2011; 8 (6): 2291-301.
94. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B: Biointerfaces 2011; 85 (2): 262-9.
95. Fan X, Chen J, Shen Q. Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery. Int J Pharm 2013; 458 (2): 296-304.
96. Sharma D, Chelvi TP, Kaur J, et al. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res 1995; 8 (7-8): 281-6.
97. Di Costanzo F, Gasperoni S, Rotella V, Di Costanzo F. Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. OncoTargets Ther 2009; 2: 179.
98. Zabaleta V, Ponchel G, Salman H, Agüeros M, Vauthier C, Irache JM. Oral administration of paclitaxel with pegylated poly (anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm 2012; 81 (3): 514-23.
99. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002; 83 (2): 273-86.
100. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004; 99 (2): 259-69.
101. Xu Z, Gu W, Huang J, et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 2005; 288 (2): 361-8.
102. Wang J, Liu W, Tu Q, et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. Biomacromolecules 2010; 12 (1): 228-34.
103. Mo Y, Lim L-Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release 2005; 108 (2): 244-62.
104. Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009; 133 (1): 11-7.
105. Akhlaghi SP, Saremi S, Ostad SN, Dinarvand R, Atyabi F. Discriminated effects of thiolated chitosan-coated pMMA paclitaxelloaded nanoparticles on different normal and cancer cell lines. Nanomed Nanotechnol Biol Med 2010; 6 (5): 689-97.
106. Danhier F, Vroman B, Lecouturier N, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release 2009; 140 (2): 166-73.
107. Al-Ghananeem AM, Malkawi AH, Muammer YM, et al. Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS Pharm 2009; 10 (2): 410-7.
108. Liu Y, Pan J, Feng S-S. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: Effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm 2010; 395 (1): 243-50.
109. Reul R, Renette T, Bege N, Kissel T. Nanoparticles for paclitaxel delivery: A comparative study of different types of dendritic polyesters and their degradation behavior. Int J Pharm 2011; 407 (1): 190-6.
110. Zhao P, Wang H, Yu M, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2012; 81 (2): 248-56.
111. Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006; 325 (1): 172-9.
112. Hwang H-Y, Kim I-S, Kwon IC, Kim Y-H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release 2008; 128 (1): 23-31.
113. Yu Y, Tan S, Zhao S, et al. Antitumor activity of docetaxel-loaded polymeric nanoparticles fabricated by Shirasu porous glass membrane-emulsification technique. Int J Nanomed 2013; 8: 2641.
114. Pradhan R, Poudel BK, Ramasamy T, Choi H-G, Yong CS, Kim JO. Docetaxel-loaded polylactic acid-co-glycolic acid nanoparticles: formulation, physicochemical characterization and cytotoxicity studies. J Nanosci Nanotechnol 2013; 13 (8): 5948-56.
115. Kulhari H, Pooja D, Shrivastava S, VGM N, Sistla R. Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel. Colloids Surf B: Biointerfaces 2014; 117: 166-73.
116. Wang H, Xu Y, Zhou X. Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: In vitro and in vivo evaluation. Int J Mol Sci 2014; 15 (3): 3519-32.
117. Esmaeili F, Ghahremani MH, Ostad SN, et al. Folate-receptortargeted delivery of docetaxel nanoparticles prepared by PLGAPEG-folate conjugate. J Drug Targeting 2008; 16 (5): 415-23.
118. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/ superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials 2011; 32 (29): 7139-50.
119. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomed 2011; 6 (1): 119-28.
120. Saremi S, Dinarvand R, Kebriaeezadeh A, Ostad SN, Atyabi F. Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies. Biomed Res Int 2013; 150478: 1-8.
121. Feng S-S, Mei L, Anitha P, Gan CW, Zhou W. Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009; 30 (19): 3297-306.
122. Werner ME, Copp JA, Karve S, et al. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano 2011; 5 (11): 8990-8.
123. Dandekar P, Jain R, Stauner T, et al. A hydrophobic starch polymer for nanoparticle-mediated delivery of docetaxel. Macromol Biosci 2012; 12 (2): 184-94.
124. Sun B, Feng S-S. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine 2009; 4 (4): 431-45.
125. Manoochehri S, Darvishi B, Kamalinia G, et al. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. DARU J Pharm Sci 2013; 21 (1): 58.
126. Luo Y, Ling Y, Guo W, et al. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release 2010; 147 (2): 278-88.
127. Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly (lactide-co-glycolide) nanoparticles. Anti-Cancer Drugs 2010; 21 (1): 43-52.
128. Liu D, Wang L, Liu Z, Zhang C, Zhang N. Preparation, characterization, and in vitro evaluation of docetaxel-loaded poly (lactic acid)-poly (ethylene glycol) nanoparticles for parenteral drug delivery. J Biomed Nanotechnol 2010; 6 (6): 675-82.
129. Keum C-G, Noh Y-W, Baek J-S, et al. Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-coglycolic acid. Int J Nanomed 2011; 6: 2225.
130. Agrawal R, Shanavas A, Yadav S, Aslam M, Bahadur D, Srivastava R. Polyelectrolyte coated polymeric nanoparticles for controlled release of docetaxel. J Biomed Nanotechnol 2012; 8 (1): 19-28.
131. Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Trans Med 2012; 4 (128): 128ra39-ra39.
132. Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li SD. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res 2013; 73 (15): 4862-71.
133. Chu KS, Schorzman AN, Finniss MC, et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials 2013; 34 (33): 8424-9.
134. Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-basednanosuspensions for active-targeted cancer therapy. Int J Nanomed 2012; 7: 3281.
135. Bensaid F, Thillaye du Boullay O, Amgoune A, et al. Y-shaped mPEG-PLA cabazitaxel conjugates: well-controlled synthesis by organocatalytic approach and self-assembly into interface drugloaded core-corona nanoparticles. Biomacromolecules 2013; 14 (4): 1189-98.
136. Gursoy N, Garrigue JS, Razafindratsita A, Lambert G, Benita S. Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. J Pharm Sci 2003; 92 (12): 2411-8.
137. Nornoo AO, Osborne DW, Chow DS-L. Cremophor-free intravenous microemulsions for paclitaxel: I: Formulation, cytotoxicity and hemolysis. Int J Pharm 2008; 349 (1): 108-16.
138. Lundberg B, Risovic V, Ramaswamy M, Wasan K. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 2003; 86 (1): 93-100.
139. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 2007; 124 (3): 163-71.
140. Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009; 71 (2): 310-7.
141. Goldstein D, Gofrit O, Nyska A, Benita S. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer. Cancer Res 2007; 67 (1): 269-75.
142. Nornoo AO, Chow DS-L. Cremophor-free intravenous microemulsions for paclitaxel: II. Stability, in vitro release and pharmacokinetics. Int J Pharm 2008; 349 (1): 117-23.
143. Gao K, Sun J, Liu K, Liu X, He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Develop Indust Pharm 2008; 34 (11): 1227-37.
144. Yin Y, Cui F, Mu C, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009; 140 (2): 86-94.
145. Li X, Du L, Wang C, Liu Y, Mei X, Jin Y. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals. Die Pharmazie-An Int J Pharm Sci 2011; 66 (7): 479-83.
146. Ma S, Chen F, Ye X, et al. Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics. Int J Nanomed 2013; 8: 4045.
147. Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68 (16): 6652-60.
148. Lay CL, Liu HQ, Tan HR, Liu Y. Delivery of paclitaxel by physically loading onto poly (ethylene glycol) (PEG)-graftcarbon nanotubes for potent cancer therapeutics. Nanotechnology 2010; 21 (6): 065101.
149. Shao W, Paul A, Zhao B, Lee C, Rodes L, Prakash S. Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model. Biomaterials 2013; 34 (38): 10109-19.
150. Sobhani Z, Dinarvand R, Atyabi F, Ghahremani M, Adeli M. Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube. Int J Nanomed 2011; 6: 705-19.
151. Wu C-H, Cao C, Kim JH, et al. Trojan-horse nanotube oncommand intracellular drug delivery. Nano Lett 2012; 12 (11): 5475-80.
152. Zhang W, Zhang D, Tan J, Cong H. Carbon nanotube exposure sensitize human ovarian cancer cells to paclitaxel. J Nanosci Nanotechnol 2012; 12 (9): 7211-4.
153. Fu X, Zhang Y, Wang X, Shou J, Zhang Z, Song L. Preparation and biological activity of a paclitaxel-single-walled carbon nanotube complex. Genet Mol Res 2013; 13 (1): 1589-603.
154. Arya N, Arora A, Vasu K, Sood A, Katti DS. Combination of single walled carbon nanotubes/graphene oxide with paclitaxel: a reactive oxygen species mediated synergism for treatment of lung cancer. Nanoscale 2013; 5 (7): 2818-29.
155. Wang L, Zhang M, Zhang N, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomed 2011; 6: 2641.
156. Arora S, Saharan R, Kaur H, Kaur I, Bubber P, Bharadwaj LM. Attachment of docetaxel to multiwalled carbon nanotubes for drug Delivery applications. Adv Sci Lett 2012; 17 (1): 70-5.
157. Zakharian TY, Seryshev A, Sitharaman B, Gilbert BE, Knight V, Wilson LJ. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc 2005; 127 (36): 12508-9.
158. Shi J, Zhang H, Wang L, et al. PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials 2013; 34 (1): 251-61.
159. Raza K, Thotakura N, Kumar P, et al. C 60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile. Int J Pharm 2015; 495 (1): 551-9.
160. Zhou Z, D’Emanuele A, Attwood D. Solubility enhancement of paclitaxel using a linear-dendritic block copolymer. Int J Pharm 2013; 452 (1): 173-9.
161. Teow HM, Zhou Z, Najlah M, Yusof SR, Abbott NJ, D’Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimerbased nanocarrier. Int J Pharm 2013; 441 (1): 701-11.
162. Cline EN, Li M-H, Choi SK, et al. Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action. Biomacromolecules 2013; 14 (3): 654-64.
163. Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: a new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 2016; 23 (4): 1204-13.
164. Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare O. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target 2011; 19 (4): 293-302.
165. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4 (2): 145-60.
166. Katare OP, Raza K. Potential and promises of phospholipidstructured carrier systems in drug delivery: A success story of antipsoriatic liposomal dithranol, PsorisomeTM, NanoColloidal Carriers: Site-soecific and Controlled Drug Delivery.” In: Vyas SP, Murthy RSR, Narang RK, Eds. NanoColloidal Carriers: Sitespecific and Controlled Drug Delivery. India: CBS Publishers 2011; pp. 77-8.
167. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172 (1): 33-70.
168. Sezgin-Bayindir Z, Onay-Besikci A, Vural N, Yuksel N. Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution. J Microencapsul 2013; 30 (8): 796-804.
169. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes— novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65 (3): 403-18.
170. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Therap 2006; 112 (3): 630-48.
171. Raza K, Kumar N, Misra C, et al. Dextran-PLGA-loaded docetaxel micelles with enhanced cytotoxicity and better pharmacokinetic profile. Int J Biol Macromol 2016; 88: 206-12.
172. Ma M, Hao Y, Liu N, et al. A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution. Int J Nanomed 2012; 7: 3389.
173. Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B: Biointerfaces 2013; 105: 67-74.
174. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47 (2): 165-96.
175. Li R, Eun JS, Lee M-K. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res 2011; 34 (2): 331-7.
176. Zhang YL, Zhang ZH, Jiang TY, et al. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells. Pharmazie 2013; 68 (1): 47-53.
177. Raza K, Singh B, Singla N, Negi P, Singal P, Katare OP. Nanolipoidal carriers of isotretinoin with anti-aging potential: formulation, characterization and biochemical evaluation. J Drug Target 2013; 21 (5): 435-42.
178. Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm 2013; 456 (1): 65-72.
179. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces 2010; 75 (1): 1-18.
180. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol 2010; 624: 163-75.
181. Wu P, Liu Q, Li R, et al. Facile preparation of paclitaxel loaded silk fibroin nanoparticles for enhanced antitumor efficacy by locoregional drug delivery. ACS Appl Mater Interfaces 2013; 5 (23): 12638-45.
182. Sharma G, Dhankar G, Thakur K, Raza K, Katare OP. Benzyl benzoate-loaded microemulsion for topical applications: enhanced dermatokinetic profile and better delivery promises. AAPS Pharm-SciTech 2015; [Epub ahead of print].
183. Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare O. Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. J Microencapsul 2011; 28 (3): 190-9.
184. Lohan S, Raza K, Singla S, et al. Studies on enhancement of antimicrobial activity of pristine MWCNTs against pathogens. AAPS PharmSciTech 2015; [Epub ahead of print].
185. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005; 9 (6): 674-9.
186. Singh B, Beg S.S, Raza K. Carbon Nano Tubes (CNTs) and their Application in Drug Delivery Systems. In: Katare OP, Ed. Recent Trends in Biotechnology. USA: Studium Press 2015; p. 9.
187. Montellano A, Da Ros T, Bianco A, Prato M. Fullerene C 60 as a multifunctional system for drug and gene delivery. Nanoscale 2011; 3 (10): 4035-41.
188. Gupta U, Agashe HB, Asthana A, Jain NK. A review of in vitro-in vivo investigations on dendrimers: the novel nanoscopic drug carriers. Nanomed: Nanotechnol Biol Med 2006; 2 (2): 66-73.
189. Rowinsky EK, Onetto N, Canetta R, Arbuck S. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19 (6): 646-62.
190. Polizzi D, Pratesi G, Monestiroli S, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 2000; 6 (5): 2070-4.
191. Sculpher M, Drummond M, O’Brien B. Effectiveness, efficiency, and NICE. BMJ 2001; 322 (7292): 943-4.